HUYA Bioscience Licenses Chidamide Cancer Compound from Chipscreen Biosciences
HUYA Bioscience Licenses Chidamide Cancer Compound from Chipscreen Biosciences
San Diego USA and Shenzhen, China – March 6, 2007 — HUYA Bioscience International, LLC, announced today that it has exclusively licensed worldwide rights outside China to the cancer compound chidamide from Shenzhen Chipscreen Biosciences Ltd.
Chidamide, is an investigational cancer compound currently approved to initiate a Phase I clinical trial in China.